STOCK TITAN

Titan Medical to Participate in H.C. Wainwright Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Titan Medical Inc. (NASDAQ: TMDI) announced that President and CEO David McNally will present the company's Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021, at 7:00 a.m. ET. The presentation will be available for on-demand viewing via the company's website. Titan Medical focuses on advancing robotic surgery technologies, with a vision to initially target gynecologic surgical indications. The company retains worldwide rights to commercialize its robotic technologies, including a license agreement with Medtronic.

Positive
  • None.
Negative
  • None.

TORONTO--(BUSINESS WIRE)-- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021. The presentation will be webcast and available on demand starting at 7:00 a.m. ET. The webcast can be accessed via the Investor Relations section of the company’s website www.titanmedicalinc.com.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with R&D facilities in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain aspects of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.

Enos™ is a trademark of Titan Medical Inc.

For more information, visit www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws. Such statements reflect the current expectations of management of the company’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to: the company’s focus on the design and development of surgical technologies for robotic single access surgery; the company’s intention to initially pursue gynecologic surgical indications with the Enos system; and the license of certain of Titan’s robotic assisted surgical technologies and related intellectual property to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the company’s Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Kristen Galfetti

Vice President, Investor Relations & Corporate Communications

+1-781-869-2553

investors@titanmedicalinc.com

Source: Titan Medical Inc.

FAQ

What is Titan Medical Inc. presenting at the H.C. Wainwright Conference?

Titan Medical Inc. is presenting its Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference.

When will Titan Medical's presentation occur?

The presentation is scheduled for Monday, September 13, 2021, at 7:00 a.m. ET.

Where can I watch Titan Medical's presentation?

The presentation will be webcast and available on demand through Titan Medical's Investor Relations section of their website.

What surgical fields is Titan Medical targeting with its Enos system?

Titan Medical intends to initially pursue gynecologic surgical indications with its Enos™ robotic surgical system.

What rights does Titan Medical have regarding its robotic technologies?

Titan Medical retains worldwide rights to commercialize its robotic assisted surgical technologies, despite licensing certain aspects to Medtronic.

TMDI

NASDAQ:TMDI

TMDI Rankings

TMDI Latest News

TMDI Stock Data

16.07M
111.59M
0.08%
4.56%
0.05%
Medical Devices
Healthcare
Link
Canada
Toronto